Top

Published in:

01-06-2011

Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors

Authors: Maria Alexiadis, Natalie Eriksson, Stacey Jamieson, Melissa Davis, Ann E. Drummond, Simon Chu, Colin D. Clyne, George E. Muscat, Peter J. Fuller

Published in: Discover Oncology | Issue 3/2011

Abstract

Granulosa cell tumors of the ovary (GCT) represent ~5% of malignant ovarian tumors. The adult form is defined by a mutation in the FOXL2 gene. GCT exhibit many of the features of normal proliferating granulosa cells. We have profiled the expression of the 48 human nuclear receptors (NR) by quantitative RT-PCR in a panel of GCT and in two GCT-derived cell lines, COV434 and KGN. The highest level of expression is seen for COUP-TF2 with abundant expression of PPARγ, SF-1, and TR-α. Estrogen receptor (ER)-β is the most abundant of the steroid receptors with relatively high expression also of AR, ER-α, and PR. The concordance of expression for each NR across the tumors is remarkably high with same discordance between the cell lines and the tumors, particularly the COV434 line. No significant differences were observed with respect to tumor stage for NR expression. These findings provide a full profile of NR expression in GCT which will enable full characterization of their roles and potential as therapeutic targets.

Available only for authorised users

Schumer ST, Cannistra SA (2003) Granulosa cell tumor of the ovary. J Clin Oncol 21:1180–1189PubMedCrossRef

Colombo N, Parma G, Zanagnolo V, Insinga A (2007) Management of ovarian stromal cell tumors. J Clin Oncol 25:2944–2951PubMedCrossRef

Young RH, Scully RE (1992) Endocrine tumours of the ovary. Curr Top Path 85:114–164

Chu S, Rushdi S, Zumpe ET, Mamers P, Healy DL, Jobling T, Burger HG, Fuller PJ (2002) FSH-regulated gene expression profiles in ovarian tumours and normal ovaries. Mol Hum Reprod 8:426–433PubMedCrossRef

Healy DL, Burger HG, Mamers P, Jobling T, Bangah M, Quinn M, Grant P, Day AJ, Rome R, Campbell JJ (1993) Elevated serum inhibin concentrations in postmenopausal women with ovarian tumors. New Eng J Med 329:1539–1542PubMedCrossRef

Jamieson S, Fuller PJ (2008) Management of granulose cell tumour of the ovary. Curr Opin Oncol 20:560–564PubMedCrossRef

Fuller PJ, Chu S (2004) Signalling pathways in the molecular pathogenesis of ovarian granulosa cell tumours. Trends Endocrinol Metab 15:122–128PubMedCrossRef

Kalfa N, Ecochard A, Patte C, Duvillard P, Audran F, Pienkowski C, Thibaud E, Brauner R, Lecointre C, Plantaz D, Guedj AM, Paris F, Baldet P, Lumbroso S, Sultan C (2006) Activating mutations of the stimulatory g protein in juvenile ovarian granulosa cell tumors: a new prognostic factor? J Clin Endocrinol Metab 91:1842–1847PubMedCrossRef

Shah SP, Kobel M, Senz J, Morin RD, Clarke BA, Wiegand KC, Leung G, Zayed A, Mehl E, Kalloger SE, Sun M, Giuliany R, Yorida E, Jones S, Varhol R, Swenerton KD, Miller D, Clement PB, Crane C, Madore J, Provender D, Leung P, DeFazio A, Khattra J, Turashvili G, Zhao YJ, Zeng T, Glover JNM, Vanderhyden B, Zhao CQ, Parkinson CA, Jimenez-Linan M, Bowtell DDL, Mes-Masson AM, Brenton JD, Aparico SA, Boyd N, Hirst M, Gilks CB, Marra M, Huntsman DG (2009) Mutation of FOXL2 in granulosa-cell tumors of the ovary. New Engl J Med 360:2719–2729PubMedCrossRef

10.

Jamieson S, Butzow R, Andersson N, Alexiadis M, Unkila-Kallio L, Heikinheimo M, Fuller PJ, Anttonen M (2010) The FOXL2 C134W mutation is characteristic of adult granulosa cell tumors of the ovary: independent confirmation from two centers. Mod Pathol 23: 1477–1485

11.

Kim MS, Hur SY, Yoo NJ, Lee SH (2010) Mutational analysis of FOXL2 codon 134 in granulosa cell tumour of ovary and other human cancers. J Pathol 221:147–152PubMedCrossRef

12.

Kalfa N, Philibert P, Patte C, Ecochard A, Duvillard P, Ecochard A, Duvillard P, Baldet P, Jaubert F, Fellous M, Sultan C (2007) Extinction of FOXL2 expression in aggressive ovarian granulosa cell tumors in children. Fertil Steril 87:896–901PubMedCrossRef

13.

Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chmbon P, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83:835–839PubMedCrossRef

14.

Gronemeyer H, Gustafsson JA, Laudet V (2004) Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 3:950–964PubMedCrossRef

15.

Chu S, Mamers P, Burger HG, Fuller PJ (2000) Estrogen receptor isoform gene expression in ovarian stromal and epithelial tumors. J Clin Endocrinol Metab 85:1200–1205PubMedCrossRef

16.

Farinola MA, Gown AM, Judson K, Ronnett BM, Barry TS, Movahedi-Lankarani S, Vang R (2007) Estrogen receptor alpha and progesterone receptor expression in ovarian adult granulosa cell tumors and Sertoli–Leydig cell tumors. Int J Gynecol Pathol 26:375–382PubMedCrossRef

17.

Zhao C, Vinh TN, McManus K, Dabbs D, Barner R, Vang R (2009) Identification of the most sensitive and robust immunohistochemical markers in different categories of ovarian sex cord-stromal tumors. Am J Surg Pathol 33:354–366PubMedCrossRef

18.

Anttonen M, Unkila-Kallio L, Leminen A, Butzow R, Heikinheimo M (2005) High GATA-4 expression associates with aggressive behavior, whereas low anti-Mullerian hormone expression associates with growth potential of ovarian granulosa cell tumors. J Clin Endocrinol Metab 90:6529–6535PubMedCrossRef

19.

van den Berg-Bakker CAM, Hagemeijer A, Franken-Postma EM, Smit VTHBM, Kuppen PJK, Claasen HHVR, Cornelisse CJ, Schrier PI (1993) Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer 53:613–620PubMedCrossRef

20.

Nishi Y, Yanase T, Mu Y, Oba K, Ichino I, Saito M, Nomura M, Mukasa C, Okabe T, Goto K, Takayanagi R, Kashimura Y, Haji M, Nawata H (2001) Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle stimulating hormone receptor. Endocrinol 142:437–445CrossRef

21.

Chu S, Nishi Y, Yanase T, Nawata H, Fuller PJ (2004) Transrepression of estrogen receptor b signalling by nuclear factor k-b in ovarian granulosa cells. Mol Endocrinol 18:1919–1928PubMedCrossRef

22.

Fuller PJ, Chu S, Jobling T, Mamers P, Healy DL, Burger HG (1999) Inhibin subunit gene expression in ovarian cancer. Gynecol Oncol 73:273–279PubMedCrossRef

23.

Hussein-Fikret S, Fuller PJ (2005) Expression of the nuclear receptor coregulators in ovarian stromal and epithelial tumours. Mol Cell Endocrinol 229:149–160PubMedCrossRef

24.

Yang X, Downes M, Yu RT, Bookout AL, He W, Straume M, Mangelsdorf DJ, Evans RM (2006) Nuclear receptor expression links the circadian clock to metabolism. Cell 126:801–810PubMedCrossRef

25.

Raichur S, Fitzsimmons RL, Myers SA, Pearen MA, Lau P, Eriksson N, Wang SM, Muscat GE (2010) Identification and validation of the pathways and functions regulated by the orphan nuclear receptor, ROR alpha1, in skeletal muscle. Nucleic Acids Res 38:4296–4312PubMedCrossRef

26.

Glover T, Mitchell K (2008) An introduction to Biostatistics, 2nd edn. Waveland Press, Long Grove

27.

Goni R, Garcia P, Foissac S (2009) The qPCR data statistical analysis. In: Integromics White Paper: Integromics SL. pp 1–9

28.

Schrader KA, Gorbatcheva B, Senz J, Heravi-Moussavi A, Melnyk N, Salamanca C, Maines-Bandiera S, Cooke SL, Leung P, Brenton JD, Gilks CB, Monahan J, Huntsman DG (2009) The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors. PLoS ONE 4(11):e7988PubMedCrossRef

29.

Benayoun BA, Caburet S, Dipietromaria A, Georges A, D'Haene B, Pandaranayaka PJ, L'Hôte D, Todeschini AL, Krishnaswamy S, Fellous M, De Baere E, Veitia RA (2010) Functional exploration of the adult ovarian granulosa cell tumor-associated somatic FOXL2 mutation p.Cys134Trp (c.402C>G). PLoS ONE 5(1):e8789PubMedCrossRef

30.

Holbeck S, Chang J, Best AM, Bookout AL, Mangelsdorf DJ, Martinez ED (2010) Expression profiling of nuclear receptors in the NC160 cancer cell panel reveals receptor-drug and receptor-gene interactions. Mol Endo 24:1287–1296CrossRef

31.

Fuller PJ, Zumpe ET, Chu S, Mamers P, Burger HG (2002) Inhibin-activin receptor subunit gene expression in ovarian tumors. J Clin Endocrinol Metab 87:1395–1401PubMedCrossRef

32.

Sato Y, Suzuki T, Hidaka K, Sato H, Ito K, Ito S, Sasano H (2003) Immunolocalization of nuclear transcription factors, DAX-1 and COUP-TF II, in the normal human ovary: correlation with adrenal 4 binding protein/steroidogenic factor-1 immunolocalization during the menstrual cycle. J Clin Endocrinol Metab 88:3415–3420PubMedCrossRef

33.

Xing W, Danilovich N, Sairam MR (2002) Orphan receptor chicken ovalbumin upstream promoter transcription factors inhibit steroid factor-1, upstream stimulatory factor, and activator protein-1 activation of ovine follicle-stimulating hormone receptor expression via composite cis-elements. Biol Reprod 66:1656–1666PubMedCrossRef

34.

Nagasaki S, Suzuki T, Miki Y, J-i A, Shibata H, Ishida T, Ohuchi N, Sasano H (2009) Chicken ovalbumin upstream promoter transcription factor II in human breast carcinoma: possible regulator of lymphangiogenesis via vascular endothelial growth factor-C expression. Cancer Sci 100:639–645PubMedCrossRef

35.

Klinge CM, Silver BF, Driscoll MD, Sathya G, Bambara RA, Hilf R (1997) Chicken ovalbumin upstream promoter-transcription factor interacts with estrogen receptor, binds to estrogen response elements and half-sites, and inhibits estrogen-induced gene expression. J Bio Chem 272:31465–31474CrossRef

36.

Riggs KA, Wickramasinghe NS, Cochrum RK, Watts MB, Klinge CM (2006) Decreased chicken ovalbumin upstream promoter transcription factor II expression in tamoxifen-resistant breast cancer cells. Cancer Res 66:10188–10198PubMedCrossRef

37.

Lee BC, Cha K, Avraham S, Avraham HK (2004) Microarray analysis of differentially expressed genes associated with human ovarian cancer. Int J Oncol 24:847–851PubMed

38.

Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P (2008) Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 18:697–704PubMedCrossRef

39.

Klopper JP, Hays WR, Sharma V, Baumbusch MA, Hershman JM, Haugen BR (2004) Retinoid X receptor-gamma and peroxisome proliferator-activated receptor-gamma expression predicts thyroid carcinoma cell response to retinoid and thiazolidinedione treatment. Mol Cancer Ther 3:1011–1020PubMed

40.

Zhang H, Li Q, Lin H, Yang Q, Wang H, Zhu C (2007) Role of PPARgamma and its gonadotrophic regulation in rat ovarian granulosa cells in vitro. Neuro Endocrinol Lett 28:289–294PubMed

41.

WuQiang F, Yanase T, Morinaga H, Mu Y-M, Nomura M, Okabe T, Goto K, Harada N, Nawata H (2004) Activation of peroxisome proliferator-activated receptor-g and retinoid X receptor inhibits aromatase transcription via nuclear factor-kB. Endocrinology 146:85–92CrossRef

42.

Lovekamp-Swan T, Chaffin CL (2005) The peroxisome proliferator-activated receptor gamma ligand troglitazone induces apoptosis and p53 in rat granulosa cells. Moll Cell Endo 233:15–24CrossRef

43.

Komar CM, Braissant O, Wahli W, Curry TE Jr (2001) Expression and localization of PPARs in the rat ovary during follicular development and the periovulatory period. Endocrinology 142:4831–4838PubMedCrossRef

44.

Banerjee J, Komar CM (2006) Effects of luteinizing hormone on peroxisome proliferator-activated receptor gamma in the rat ovary before and after the gonadotropin surge. Reprod 131:93–101CrossRef

45.

Komar CM, Curry TE Jr (2003) Inverse relationship between the expression of messenger ribonucleic acid for peroxisome proliferator-activated receptor gamma and P450 side chain cleavage in the rat ovary. Biol Reprod 69:549–555PubMedCrossRef

46.

Seto-Young D, Avtanski D, Strizhevsky M, Parikh G, Patel P, Kaplun J, Holcomb K, Rosenwaks Z, Poretsky L (2007) Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. J Clin Endocrinol Metab 92:2232–2239PubMedCrossRef

47.

Kowalewski MP, Dyson MT, Manna PR, Stocco DM (2009) Involvement of peroxisome proliferator-activated receptor gamma in gonadal steroidogenesis and steroidogenic acute regulatory protein expression. Reprod Fertil Dev 21:909–922PubMedCrossRef

48.

Mu YM, Yanase T, Nishi Y, Waseda N, Oda T, Tanaka A, Takayanagi R, Nawata H (2000) Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells. Biochem Biophys Res Commun 271:710–713PubMedCrossRef

49.

Fan W, Yanase T, Morinaga H, Mu YM, Nomura M, Okabe T, Goto K, Harada N, Nawata H (2005) Activation of peroxisome proliferator-activated receptor-g and retinoid X receptor inhibits aromatase transcription via nuclear factor-kB. Endocrinology 146:85–92PubMedCrossRef

50.

Gasic S, Bodenburg Y, Nagamani M, Green A, Urban RJ (1998) Troglitazone inhibits progesterone production in porcine granulosa cells. Endocrinology 139:4962–4966PubMedCrossRef

51.

Gasic S, Nagamani M, Green A, Urban RJ (2001) Troglitazone is a competitive inhibitor of 3beta-hydroxysteroid dehydrogenase enzyme in the ovary. Am J Obstet Gynceol 184:575–579CrossRef

52.

Kim J, Sato M, LiQ LJP, Demayo FJ, Bagchi IC, Bagchi MK (2008) Peroxisome proliferator-activated receptor gamma is a target of progesterone regulation in the preovulatory follicles and controls ovulation in mice. Mol Cell Biol 28:1770–1782PubMedCrossRef

53.

Falzacappa CV, Mangialardo C, Patriarca V, Bucci B, Amendola D, Raffa S, Torrisi MR, Silvestrini G, Ballanti P, Moriggi G, Stigliano A, Brunetti E, Toscano V, Misiti S (2009) Thyroid hormones induce cell proliferation and survival in ovarian granulosa cells COV434. J Cell Physiol 221:242–253CrossRef

54.

Zhang SS, Carrillo AJ, Darling DS (1997) Expression of multiple thyroid hormone receptor mRNAs in human oocytes, cumulus cells, and granulosa cells. Mol Hum Reprod 3:555–562PubMedCrossRef

55.

Aghajanova L, Lindeberg M, Carlsson IB, Stavreus-Evers A, Zhang P, Scott JE, Hovatta O, Skjöldebrand-Sparre L (2009) Receptors for thyroid-stimulating hormone and thyroid hormones in human ovarian tissue. Reprod Biomed Online 18:337–347PubMedCrossRef

56.

Wikstrom L, Johansson C, Salto C, Barlow C, Campos Barros A, Baas F, Forrest D, Thoren P, Vennstrom B (1998) Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J 17:455–461PubMedCrossRef

57.

Martinez-Iglesias O, Garcia-Silva S, Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennstrom B, Aranda A (2009) Thyroid hormone receptor beta1 acts as a potent suppressor of tumor invasiveness and metastasis. Cancer Res 69:501–509PubMedCrossRef

58.

Luo X, Ikeda Y, Parker KL (1994) A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 77:481–490PubMedCrossRef

59.

Jeyasuria P, Ikeda Y, Jamin SP, Zhao L, de Rooij DG, Themmen AP, Behringer RR, Parker KL (2004) Cell-specific knockout of steroidogenic factor 1 reveals its essential roles in gonadal function. Mol Endocrinol 18:1610–1619PubMedCrossRef

60.

Pelusi C, Ikeda Y, Zubair M, Parker KL (2008) Impaired follicle development and infertility in female mice lacking steroidogenic factor 1 in ovarian granulosa cells. Biol Reprod 79:1074–1083PubMedCrossRef

61.

Biason-Lauber A, Schoenle EJ (2000) Apparently normal ovarian differentiation in a prepubertal girl with transcriptionally inactive steroidogenic factor 1 (NR5A1/SF-1) and adrenocortical insufficiency. Am J Hum Genet 67:1563–1568PubMedCrossRef

62.

Lourenco D, Brauner R, Lin L, De PA, Weryha G, Muresan M, Boudjenah R, Guerra-Junior G, iel-Guerra AT, Achermann JC, McElreavey K, Bashamboo A (2009) Mutations in NR5A1 associated with ovarian insufficiency. N Engl J Med 360:1200–1210PubMedCrossRef

63.

Pare JF, Malenfant D, Courtemanche C, Jacob-Wagner M, Roy S, Allard D, Belanger L (2004) The fetoprotein transcription factor (FTF) gene is essential to embryogenesis and cholesterol homeostasis, and regulated by a DR4 element. J Biol Chem 279:21206–21216PubMedCrossRef

64.

Duggavathi R, Volle DH, Mataki C, Antal MC, Messaddeq N, Auwerx J, Murphy BD, Schoonjans K (2008) Liver receptor homolog 1 is essential for ovulation. Genes Dev 22:1871–1876PubMedCrossRef

65.

Hinshelwood MM, Repa JJ, Shelton JM, Richardson JA, Mangelsdorf DJ, Mendelson CR (2003) Expression of LRH-1 and SF-1 in the mouse ovary: localization in different cell types correlates with differing function. Mol Cell Endo 207:39–45CrossRef

66.

Falender AE, Lanz R, Malenfant D, Belanger L, Richards JS (2003) Differential expression of steroidogenic factor-1 and FTF/LRH-1 in the rodent ovary. Endocrinology 144:3598–3610PubMedCrossRef

67.

Takayama K, Sasano H, Fukaya T, Morohashi K, Suzuki T, Tamura M, Costa MJ, Yajima A (1995) Immunohistochemical localization of Ad4-binding protein with correlation to steroidogenic enzyme expression in cycling human ovaries and sex cord stromal tumors. J Clin Endocrinol Metab 80:2815–2821PubMedCrossRef

68.

Saxena D, Escamilla-Hernandez R, Little-Ihrig L, Zeleznik AJ (2007) Liver receptor homolog-1 and steroidogenic factor-1 have similar actions on rat granulosa cell steroidogenesis. Endocrinology 148:726–734PubMedCrossRef

69.

Saxena D, Safi R, Little-Ihrig L, Zeleznik AJ (2004) Liver receptor homolog-1 stimulates the progesterone biosynthetic pathway during follicle-stimulating hormone-induced granulosa cell differentiation. Endocrinology 145:3821–3829PubMedCrossRef

70.

Yazawa T, Inaoka Y, Okada R, Mizutani T, Yamazaki Y, Usami Y, Kuribayashi M, Orisaka M, Umezawa A, Miyanoto K (2010) PPAR-g coactivator-1a regulates progesterone production in ovarian granulosa cells with SF-1 and LRH-1. Mol Endo 24:485–496CrossRef

71.

Weck J, Mayo KE (2006) Switching of NR5A proteins associated with the inhibin alpha-subunit gene promoter after activation of the gene in granulosa cells. Mol Endo 20:1090–1103CrossRef

72.

Robert NM, Miyamoto Y, Taniguchi H, Viger RS (2006) LRH-1/NR5A2 cooperates with GATA factors to regulate inhibin a-subunit promoter activity. Mol Cell Endo 257:65–74CrossRef

73.

Kyronlahti A, Kauppinen M, Lind E, Unkila-Kallio L, Butzow R, Klefstrom J, Wilson DB, Anttonen M, Heikinheimo M (2010) GATA4 protects granulosa cell tumors from TRAIL-induced apoptosis. Endocr Relat Cancer 17:709–717PubMedCrossRef

74.

Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, Cavalli LR, Virolle V, Barbry P, Zambetti GP, Figueiredo BC, Heckert LL, Lalli E (2007) Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol 21:2968–2987PubMedCrossRef

75.

Doghman M, Cazareth J, Douguet D, Madoux F, Hodder P, Lalli E (2009) Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonist. J Clin Endocrinol Metab 94:2178–2183PubMedCrossRef

76.

Botrugno OA, Fayard E, Annicotte JS, Haby C, Brennan T, Wendling O, Tanaka T, Kodama T, Thomas W, Auwerx J, Schoonjans K (2004) Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Mol Cell 15:499–509PubMedCrossRef

77.

Schoonjans K, Dubuquoy L, Mebis J, Fayard E, Wendling O, Haby C, Geboes K, Auwerx J (2005) Liver receptor homolog 1 contributes to intestinal tumor formation through effects on cell cycle and inflammation. Proc Natl Acad Sci USA 102:2058–2062PubMedCrossRef

78.

Modica S, Gofflot F, Murzilli S, D'Orazio A, Salvatore L, Pellegrini F, Nicolucci A, Tognoni G, Copetti M, Valanzano R, Veschi S, Mariani-Costantini R, Palasciano G, Schoonjans K, Auwerx J, Moschetta A (2010) The intestinal nuclear receptor signature with epithelial localization patterns and expression modulation in tumors. Gastroenterology 138:636–648PubMedCrossRef

79.

Kuiper GG, Gustafsson JA (1997) The novel estrogen receptor-beta subtype: potential role in the cell- and promoter-specific actions of estrogens and anti-estrogens. FEBS Lett 410:87–90PubMedCrossRef

80.

Drummond AE, Fuller PJ (2010) The importance of ERbeta signaling in the ovary. J Endocrinol 205:15–23PubMedCrossRef

81.

Weil SJ, Vendola K, Zhou J, Adesanya OO, Wang J, Okafor J, Bondy CA (1998) Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab 83:2479–2485PubMedCrossRef

82.

Walters KA, Allan CM, Handelsman DJ (2008) Androgen actions and the ovary. Biol Reprod 78:380–389PubMedCrossRef

83.

Hu YC, Wang PH, Yeh S, Wang RS, Xie C, Xu O, Zhou X, Chao HT, Tsai MY, Chang C (2004) Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Proc Natl Acad Sci USA 101:11209–11214PubMedCrossRef

84.

Sen A, Hammes SR (2010) Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol 24:1393–1403PubMedCrossRef

85.

Sriraman V, Sinha M, Richards JS (2010) Progesterone receptor-induced gene expression in primary mouse granulosa cell cultures. Biol Reprod 82:402–412PubMedCrossRef

86.

Friberg PA, Larsson DG, Billig H (2009) Dominant role of nuclear progesterone receptor in the control of rat periovulatory granulosa cell apoptosis. Biol Reprod 80:1160–1167PubMedCrossRef

87.

Shyr CR, Hu YC, Kim E, Chang C (2002) Modulation of estrogen receptor-mediated transactivation by orphan receptor TR4 in MCF-7 cells. J Biol Chem 277:14622–14628PubMedCrossRef

88.

Chen LM, Wang RS, Lee YF, Liu NC, Chang YJ, Wu CC, Xie S, Hung YC, Chang C (2008) Subfertility with defective folliculogenesis in female mice lacking testicular orphan nuclear receptor 4. Mol Endo 22:858–867CrossRef

89.

Steffensen KR, Robertson K, Gustafasson JA, Andersen CY (2006) Reduced fertility and inability of oocytes to resume meiosis in mice deficient of the Lxr genes. Mol Cell Endo 256:9–16CrossRef

90.

Mouzat K, Volat F, Baron S, Alves G, Pommier AJ, Volle DH, Marceau G, Dehaze A, DŠchelotte P, Duggavathi R, Caira F, Lobaccaro JM (2009) Absence of nuclear receptors for oxysteroid Liver X Receptor (LXR) induces ovarian hyperstimulation syndrome in mice. Endocrinology 150:3369–3375PubMedCrossRef

91.

Drouineaud V, Sagot P, Garrido C, Logette E, Deckert V, Gambert P, Jimenez C, Staels B, Lagrost L, Masson D (2007) Inhibition of progesterone production in human luteinized granulosa cells treated with LXR agonists. Mol Hum Reprod 13:373–379PubMedCrossRef

92.

Teboul M, Guillaumond F, GrŠchez-Cassiau A, Delaunay F (2008) The nuclear hormone receptor family round the clock. Mol Endo 22:2573–2582CrossRef

93.

Chomez P, Neveu I, Mansén A, Kiesler E, Larsson L, Vennstrom B, Arenas E (2000) Increased cell death and delayed development in the cerebellum of mice lacking the rev-erbA(alpha) orphan receptor. Development 127:1489–1498PubMed

94.

Kang HS, Angers M, Beak JY, Wu X, Gimble JM, Wada T, Xie W, Collins JB, Grissom SF, Jetten AM (2007) Gene expression profiling reveals a regulatory role for ROR alpha and ROR gamma in phase I and phase II metabolism. Physiol Genomics 31:281–294PubMedCrossRef

95.

Odawara H, Iwasaki T, Horiguchi J, Rokutanda N, Hirooka K, Miyazaki W, Koibuchi Y, Shimokawa N, Iino Y, Takeyoshi I, Koibuchi N (2009) Activation of aromatase expression by retinoic acid receptor-related orphan receptor (ROR) alpha in breast cancer cells: identification of a novel ROR response element. J Biol Chem 284:17711–17719PubMedCrossRef

96.

Zhu Y, McAvoy S, Kuhn R, Smith DI (2006) RORA, a large common fragile site gene, is involved in cellular stress response. Oncogene 25:2901–2908PubMedCrossRef

97.

Wu Y, Ghosh S, Nishi Y, Yanase T, Nawata H, Hu Y (2005) The orphan nuclear receptors NURR1 and NGFI-B modulate aromatase gene expression in ovarian granulosa cells: a possible mechanism for repression of aromatase expression upon luteinizing hormone surge. Endocrinology 146:237–246PubMedCrossRef

98.

Zhang T, Wang P, Ren H, Fan J, Wang G (2009) NGFI-B nuclear orphan receptor Nurr1 interacts with p53 and suppresses its transcriptional activity. Mol Cancer Res 7:1408–1415PubMedCrossRef

Title: Nuclear Receptor Profiling of Ovarian Granulosa Cell Tumors
Authors: Maria Alexiadis
Natalie Eriksson
Stacey Jamieson
Melissa Davis
Ann E. Drummond
Simon Chu
Colin D. Clyne
George E. Muscat
Peter J. Fuller
Publication date: 01-06-2011
Publisher: Springer-Verlag
Published in: Discover Oncology / Issue 3/2011
Print ISSN: 1868-8497
Electronic ISSN: 2730-6011
DOI: https://doi.org/10.1007/s12672-011-0069-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Inhibitory Effects of Calcitriol on the Growth of MCF-7 Breast Cancer Xenografts in Nude Mice: Selective Modulation of Aromatase Expression in vivo

Role for MicroRNAs in Regulating Glucocorticoid Response and Resistance in Multiple Myeloma

Progesterone Receptor-B Induction of BIRC3 Protects Endometrial Cancer Cells from AP1-59-Mediated Apoptosis

Testosterone Regulates Tight Junction Proteins and Influences Prostatic Autoimmune Responses

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials